Roche Restarts Phase III Trial for Elevidys to Secure EMA Approval
Written By : sheeba farhat
Published On 2026-04-17 10:44 GMT | Update On 2026-04-17 10:44 GMT
New Delhi: Roche on Thursday said it is initiating a late stage study for its gene therapy Elevidys following feedback from the European drug regulator. The therapy for duchenne muscular dystrophy (DMD), for which Roche partners with American Sarepta Therapeutics had failed to win backing from the European Medicines Agency (EMA) last year after coming under scrutiny following two patient deaths tied to the treatment.
- The phase III study aims to generate additional placebo-controlled data required for a regulatory re-submission with EMA.
- Elevidys is currently approved in nine countries for ambulatory boys with a confirmed DMD mutation, including in the United States, which had temporarily ordered a pause in shipments last July.
- DMD is a rare, inherited disease that mostly affects boys and causes muscles to weaken steadily over time.
- The study will span more than 72 weeks and evaluate the efficacy and safety of Elevidys compared to placebo in around 100 early ambulatory boys with DMD. The primary endpoint is the change in the so-called "time to rise" from the floor velocity.
- "Our confidence is rooted in robust long-term data showing the durable efficacy and safety of Elevidys, alongside the experience of treating more than a thousand ambulatory boys worldwide," Roche's Chief Medical Officer and Head of Global Product Development Levi Garraway said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.